Release Date: November 30, 2022
Expiration Date: November 30, 2023

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, three experts discuss the spectrum of care for patients with diffuse large B-cell lymphoma (DLBCL). Dr. Armitage will begin by reviewing the history of treatment advances and the new classification of DLBCL. Dr. Leonard will discuss current data regarding investigational frontline therapies. Lastly, Dr. Westin will describe new targets and novel therapies in relapsed/refractory disease and beyond. This program concludes with an in-depth discussion on applying this information to current practice.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with diffuse large B-cell lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Recall evidence-based guideline recommendations for frontline and relapsed/refractory DLBCL treatment
• Discuss emerging and newly approved therapies for frontline and relapsed/refractory DLBCL treatment
• Identify barriers to optimal treatment of DLBCL that can influence both treatment quality and DLBCL outcomes, including disparities in care, geographic factors, and patient factors
• Summarize key data on DLBCL presented at ASH 2021 and other national conferences and relevant points for practice

Agenda

Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma – James O. Armitage, MD; John P. Leonard, MD; and Jason Westin, MD, MS, FACP

Instructions for Participation and Credit

This activity is eligible for credit through November 30, 2023. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

James O. Armitage, MD
Joe Shapiro Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Dr. James Armitage received his medical degree from the University of Nebraska Medical Center, where he also completed his internship and residency in internal medicine. In addition, he completed a fellowship in hematology/oncology at the University of Iowa. Dr. Armitage is the Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center where he developed the Bone Marrow Transplant program and the Nebraska Lymphoma Study Group. He has also served as Vice Chair of Internal Medicine, Chief of the Section of Oncology and Hematology, Chair of the Department of Internal Medicine, and Dean of the College of Medicine.

Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, and is a fellow of the American and the Royal College of Physicians, ASCO, the American Association for the Advancement of Science, and American Society for Transplantation and Cellular Therapy (ASTCT). He has served on many national/international oncology committees, including the United States National Cancer Advisory Board and the French National Cancer Advisory Board. He is past president of both the American Society of Clinical Oncology and the American Society of Blood and Marrow Transplantation. Dr. Armitage has published more than 600 papers, written 115 chapters, and is editor/co-editor of 33 books. He currently edits the ASCO Post and has received numerous honors.

John P. Leonard, MD
Richard T. Silver Distinguished Professor
Hematology and Medical Oncology
Weill Cornell Medicine

Dr. John Leonard received his medical degree at the University of Virginia School of Medicine. He completed his residency in medicine at the New York Hospital - Cornell Medical Center and Memorial Sloan-Kettering Cancer Center, his fellowship in hematology and oncology at Cornell, and he served as the chief medical resident at the New York Hospital - Cornell Medical Center. Dr. Leonard is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and Senior Associate Dean for Innovation and Initiatives at Weill Cornell Medicine. In addition, he is Executive Vice Chairman of the Weill Department of Medicine at Weill Cornell Medicine and New York-Presbyterian Hospital, where he also serves as an Attending Physician.

An expert in hematology and oncology, Dr. Leonard’s research has been published in numerous medical journals, and he has served as a member of the editorial boards of Blood and the Journal of Clinical Oncology. He is Chair of the Lymphoma Committee of the Alliance for Clinical Trials. Dr. Leonard has been a member of the American Board of Internal Medicine subspecialty board for Hematology and the American Society of Clinical Investigation. He has served as Chair of the Scientific Advisory Board, Board Member of the Lymphoma Research Foundation, and Board Member of the Leukemia and Lymphoma Society/New York City Chapter.

Dr. Leonard’s primary research interest is in the development of novel therapeutic strategies for the treatment of lymphoma and related hematologic malignancies, and he has lectured at major international meetings on these topics. Much of his work has involved the development of novel therapies for lymphoma, including monoclonal antibodies, other immune-based treatments, targeted agents and other innovative approaches. He also has studied prognostic, imaging and survivorship issues for lymphoma patients.

Jason Westin, MD, MS, FACP
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Dr. Jason Westin is the Director of Lymphoma Clinical Research and the Section Chief for Aggressive Lymphoma at MD Anderson Cancer Center in Houston. He is the leader of the diffuse large B-cell lymphoma research team at the University of Texas MD Anderson Cancer Center in the Department of Lymphoma and Myeloma.

Dr. Westin’s research interests include designing and conducting innovative clinical trials, and the development of new drugs and new methods to improve outcomes for patients with lymphoma, including the study of scale-free networks and complex systems. He believes that clinical research is our best weapon in the fight against cancer, and has designed and conducted numerous clinical trials to find new cures for cancer. He has presented his research at national and international conferences, including the American Society of Hematology, the American Society of Clinical Oncology, the American College of Clinical Pharmacology, the Lymphoma Research Foundation, and in Japan, Thailand, China, Spain, Switzerland, Belgium, Canada, and Peru. Dr. Westin has received multiple awards to fund his research.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-017-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
	NURSING CREDIT MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-017-157

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. James Armitage has relevant financial relationships related to advisory activities from Cardiff Oncology, Inc.

Dr. John Leonard has relevant financial relationships related to consulting from AbbVie Inc., Astellas Pharma US, Inc., BeiGene, Calithera BioSciences, Inc., Celgene Corporation ‒ A Bristol Myers Squibb Company, Constellation Pharmaceuticals, Eisai Co., Ltd., Eli Lilly and Company, Epizyme, Inc., Genentech - A Member of the Roche Group, Genmab A/S, Grail, Inc., Incyte Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Mustang Bio, Second Genome, Pfizer Inc., and Sutro Biopharma.

Dr. Jason Westin has relevant financial relationships related to advisory activities and has received research grant(s) from ADC Therapeutics SA, AstraZeneca, Bristol Myers Squibb Company, Genentech, Inc. Kite Pharma/Gilead, MorphoSys, Novartis AG, Iksuda Therapeutics, and Merck & Co., Inc., in addition to advisory activities from Monte Rosa Therapeutics, and Umoja Biopharma.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding the content of this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group.

©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.